Dr. Hasserjian works closely with oncologists and other hematologists to provide optimal patient care. He lectures regularly at continuing medical education courses at medical schools throughout the United States.



Centers & Specialties

Cancer Center

Clinical Interests
  • Hematopathology
  • Gastrointestinal (GI) pathology
Medical Education
  • MD, Harvard Medical School
  • Residency, Brigham and Women's Hospital
  • Fellowship, Brigham and Women's Hospital
Board Certifications
  • Anatomic Pathology
  • Hematology
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Medicaid
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group
Adult and Pediatric

Edit Profile


Dr. Hasserjian's clinical work and research focus on myeloid neoplasia.  He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.

Edit Profile

Research & Publications

Research Summary

Dr. Hasserjian's research interests include:

  • Molecular mechanisms of leukemia and lymphoma.
  • Novel pathologic, immunophenotypic, and molecular prognostic markers in myelodysplastic and myeloproliferative diseases, leukemias, and lymphomas

For more information about research concepts, co-authors, and to see a timeline, visit  Dr. Hasserjian?s profile at the Harvard Clinical and Translational Science Center.


View my most recent publications at PubMed

  1. Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle? Tandon B, Swerdlow SH, Hasserjian RP, Surti U, Gibson SE.Leuk Lymphoma. 2015 Apr 10:1-33. [Epub ahead of print]
  2. Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Nardi V, Pulluqi O, Abramson JS, Dal Cin P, Hasserjian RP.  Am J Hematol. 2015 Mar 16.[Epub ahead of print]
  3. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R. Bone Marrow Transplant. 2015 Feb 9. doi: 10.1038/bmt.2014.323. [Epub ahead of print]

Edit Profile


Pathology Associates
55 Fruit Street
Boston MA, 02114-2696
Phone: 617-724-1445
Fax: 617-726-7474

Edit Profile